SciELO - Scientific Electronic Library Online

 
vol.7 issue2Seguridad y viabilidad de la prueba ergométrica en pacientes con insuficiencia cardíacaParadoja de la obesidad author indexsubject indexarticles search
Home Pagealphabetic serial listing  

Services on Demand

Article

Indicators

  • Have no cited articlesCited by SciELO

Related links

  • On index processCited by Google
  • Have no similar articlesSimilars in SciELO
  • On index processSimilars in Google

Bookmark


Insuficiencia cardíaca

On-line version ISSN 1852-3862

Abstract

SOSA LIPRANDI, Alvaro et al. Role of aldosterone blockade in heart failure post acute myocardial infarction. Insuf. card. [online]. 2012, vol.7, n.2, pp. 61-66. ISSN 1852-3862.

Cardiac remodeling remains the leading cause of heart failure (HF) progression and death after an acute myocardial infarction (AMI). Therapeutic strategies directed towards physiopathologic mechanisms of healing and remodeling seems to be useful means to prevent progressive functional impairment, arrhythmias and congestive heart failure. In two consecutive meetings, 50 experts critically reviewed the available evidence. The present document reflects the consensus of the subject: "Role of aldosterone blockade in heart failure post acute myocardial infarction". Clinical interest in blocking aldosterone in patients treated with an angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs) was stimulated by the Randomized Aldactone Evaluation Study (RALES), which demonstrated that the mineralocorticoid (MC) antagonist spironolactone reduced the risk of all-cause mortality as well as hospitalizations for HF in patients with severe NYHA class III-IV HF and a reduced left ventricular ejection fraction (LVEF). Shortly after, the post Acute Myocardial Infarction Heart failure Efficacy and Survival Study (EPHESUS) showed a benefit of the second-generation MR antagonist eplerenone on all-cause mortality as well as hospitalizations for HF early post-AMI. Concluding that the current indications for aldosterone blockers are therefore clear for patients with moderate to severe symptoms (NYHA functional class III-IV), who have a decrease LVEF and signs and symptoms of heart failure despite optimal background treatment. The guidelines also support the use of these drugs in patients with left ventricular dysfunction after AMI

Keywords : Blocking aldosterone; Heart failure; Acute myocardial infarction.

        · abstract in Spanish | Portuguese     · text in Spanish     · pdf in Spanish